8 November 2022 - The US FDA and the EMA agreed on nearly two-thirds of decisions to grant or deny requests for drugs and biologics seeking breakthrough therapy or Priority Medicines designation, according to a new analysis.

The findings highlight the need for agencies and sponsors to take advantage of collaborative opportunities, including the parallel scientific Advice program, to support global drug development that addresses unmet medical needs.

Read Regulatory Affairs Professional Society article